Abstract
Neuropsychiatric symptoms are often seen in patients with systemic lupus erythematosus (SLE). To investigate the relationship between involvement of the nervous system and clinical factors, including autoantibodies and the activity of SLE, we retrospectively reviewed 25 patients with neuropsychiatric SLE (NPSLE, mean age: 35.2±12.2 years). As controls 37 SLE patients without neuropsychiatric manifestations (mean age: 31.8±15.8 years) were employed in this study. At the onset no significant differences were seen in any clinical factors between the patients and the controls except for serum antinuclear antibodies. In relapse, the patients with NPSLE showed significantly lower levels of Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores without neuropsychiatric evaluation (p<0.0001), erythrocyte sedimentation rate (ESR, p<0.005), and antinuclear and anti-double-stranded DNA antibodies (p<0.005) and higher WBC values (p<0.05) than at the onset. Also in the patients with relapsing NPSLE similar significant differences were seen in these parameters between onset and relapse (p<0.005). Despite a lack of significant differences, the cerebrospinal fluid showed lower values in cell counts, total protein, and IgG in relapse than at onset. These results suggest that there are no clinical factors that predict the development of NPSLE and that relapse can occur with low disease activity in the nervous system even with an inactive state of other organ involvement. Since NPSLE may suddenly relapse with a slight change in common disease activation markers, including inflammatory reactions, autoantibodies, and complements in serum and CSF findings, adequate corticosteroid and/or immunosuppressive agents should be given at the onset and gradually be tapered after recovery, while looking out for recurrence.
Similar content being viewed by others
References
Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A (2001) The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 57:496–500
Hanly JG (2001) Neuropsychiatric lupus. Curr Rheumatol Rep 3:205–212
ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature (1999) The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 42:599–608
Hanly JG, Fisk JD, Sherwood G, Jones E, Jones JV, Eastwood B (1992) Cognitive impairment in patients with systemic lupus erythematosus. J Rheumatol 19:562–567
Jennekens FG, Kater L (2002) The central nervous system in systemic lupus erythematosus. Part 2. Pathogenetic mechanisms of clinical syndromes: a literature investigation. Rheumatology (Oxford) 41:619–630
Hirohata S, Miyamoto T (1990) Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum 33:644–649
Hirohata S, Kosaka M (1994) Association of anti-Sm antibodies with organic brain syndrome secondary to systemic lupus erythematosus. Lancet 343:796
Swaak AJ, Huysen V, Nossent JC, Smeenk RJ (1990) Antinuclear antibody profiles in relation to specific disease manifestations of systemic lupus erythematosus. Clin Rheumatol 9:82–94
Silva LM, Garcia AB, Donadi EA (2002) Increased lymphocyte death by neglect-apoptosis is associated with lymphopenia and autoantibodies in lupus patients presenting with neuropsychiatric manifestations. J Neurol 249:1048–1054
Isshi K, Hirohata S (1998) Differential roles of the anti-ribosomal P antibody and antineuronal antibody in the pathogenesis of central nervous system involvement in systemic lupus erythematosus. Arthritis Rheum 41:1819–1827
Gerli R, Caponi L, Tincani A, Scorza R, Sabbadini MG, Danieli MG et al (2002) Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. Rheumatology (Oxford) 41:1357–1366
Yoshio T, Masuyama J, Kano S (1996) Antiribosomal P0 protein antibodies react with the surface of human umbilical vein endothelial cells. J Rheumatol 23:1311–1312
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277
Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725
Finn R, de M Rudolf N (1978) The electroencephalogram in systemic lupus erythematosus. Lancet 1:1255
Ishikawa O, Ohnishi K, Miyachi Y, Ishizaka H (1994) Cerebral lesions in systemic lupus erythematosus detected by magnetic resonance imaging. Relationship to anticardiolipin antibody. J Rheumatol 21:87–90
Sibbitt WL Jr, Schmidt PJ, Hart BL, Brooks WM (2003) Fluid attenuated inversion recovery (FLAIR) imaging in neuropsychiatric systemic lupus erythematosus. J Rheumatol 30:1983–1989
Small P, Mass MF, Kohler PF, Harbeck RJ (1977) Central nervous system involvement in SLE. Diagnostic profile and clinical features. Arthritis Rheum 20:869–878
Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35:630–640
Hirohata S, Hirose S, Miyamoto T (1985) Cerebrospinal fluid IgM, IgA, and IgG indexes in systemic lupus erythematosus. Arch Intern Med 145:1843–1846
Neuwelt CM, Lacks S, Kaye BR, Ellman JB, Borenstein DG (1995) Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med 98:32–41
Hanly JG, Walsh NM, Sangalang V (1992) Brain pathology in systemic lupus erythematosus. J Rheumatol 19:732–741
Devinsky O, Petito CK, Alonso DR (1988) Clinical and neuropathological findings in systemic lupus erythematosus: the role of vasculitis, heart emboli, and thrombotic thrombocytopenic purpura. Ann Neurol 23:380–384
Zvaifler NJ, Bluestein HG (1982) The pathogenesis of central nervous system manifestations of systemic lupus erythematosus. Arthritis Rheum 25:862–866
Ellis SG, Verity MA (1971) Central nervous system involvement in systemic lupus erythematosus: a review of neuropathologic findings in 57 cases, 1955–1977. Semin Arthritis Rheum 8:212–221
Afeltra A, Garzia P, Mitterhofer AP, Vadacca M, Galluzzo S, Del Porto F et al (2003) Neuropsychiatric lupus syndromes: relationship with antiphospholipid antibodies. Neurology 61:108–110
Karassa FB, Ioannidis JP, Boki KA, Touloumi G, Argyropoulou MI, Strigaris KA et al (2000) Predictors of clinical outcome and radiologic progression in patients with neuropsychiatric manifestations of systemic lupus erythematosus. Am J Med 109:628–634
Sabet A, Sibbitt WL Jr, Stidley CA, Danska J, Brooks WM (1998) Neurometabolite markers of cerebral injury in the antiphospholipid antibody syndrome of systemic lupus erythematosus. Stroke 29:2254–2260
Winfield JB, Shaw M, Silverman LM, Eisenberg RA, Wilson HA III, Koffler D (1983) Intrathecal IgG synthesis and blood-brain barrier impairment in patients with systemic lupus erythematosus and central nervous system dysfunction. Am J Med 74:837–844
McLean BN, Miller D, Thompson EJ (1995) Oligoclonal banding of IgG in CSF, blood-brain barrier function, and MRI findings in patients with sarcoidosis, systemic lupus erythematosus, and Behçet’s disease involving the nervous system. J Neurol Neurosurg Psychiatry 58:548–554
Pradhan VD, Badakere SS, Bichile LS, Dolas MP (2002) Antibodies to Ro/SS-A and La/SS-B in systemic lupus erythematosus and other autoimmune disorders. J Assoc Physicians India 50:762–765
Hirohata S, Hayakawa K (1999) Enhanced interleukin-6 messenger RNA expression by neuronal cells in a patient with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 42:2729–2730
Shiozawa S, Kuroki Y, Kim M, Hirohata S, Ogino T (1992) Interferon-alpha in lupus psychosis. Arthritis Rheum 35:417–422
El-Zorkany BK, Mahmoud GA, Shahin HA, Moustafa H, Shahin AA (2003) Tumor necrosis factor-alpha and neuropsychiatric lupus erythematosus: relation to single photon emission computed tomography findings. Mod Rheumatol 13:250–255
Acknowledgments
This work was supported by a grant from the Neuroimmunological Disease Research Committee of the Intractable Disease Division, the Ministry of Public Health, Labor and Welfare, Japan.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shimojima, Y., Matsuda, M., Gono, T. et al. Relationship between clinical factors and neuropsychiatric manifestations in systemic lupus erythematosus. Clin Rheumatol 24, 469–475 (2005). https://doi.org/10.1007/s10067-004-1060-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-004-1060-y